Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Eastern Cooperative Oncology Group
Colorado State University
Zagazig University
Penn State University
University Health Network, Toronto
Essen Biotech
Brigham and Women's Hospital
Institut BergoniƩ
Duke University
University of Oklahoma
M.D. Anderson Cancer Center
OncoNano Medicine, Inc.
University of Salamanca
AC Camargo Cancer Center
Incyte Corporation
Immunitas Therapeutics
M.D. Anderson Cancer Center
Arab American University (Palestine)
Washington University School of Medicine
Washington University School of Medicine
Abramson Cancer Center at Penn Medicine
University Health Network, Toronto
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
RAPT Therapeutics, Inc.
University of Toronto
Cedars-Sinai Medical Center
Rigshospitalet, Denmark
Eisai Inc.
Association Francaise pour la Recherche Thermale
Haukeland University Hospital
Icahn School of Medicine at Mount Sinai
Eastern Cooperative Oncology Group
National Cheng-Kung University Hospital
Mayo Clinic
Fate Therapeutics
Virginia Commonwealth University
Insel Gruppe AG, University Hospital Bern
Genzada Pharmaceuticals USA, Inc.
Blue Note Therapeutics
Harvard School of Public Health (HSPH)
Eli Lilly and Company
Incyte Corporation
Wake Forest University Health Sciences
AstraZeneca